curetoday.com
New Bispecific Antibody 'Etentamig' Shows Significant Efficacy in Advanced Multiple Myeloma, Reducin
A recent Phase 3 clinical trial highlighted a new bispecific antibody, etentamig, as a promising treatment for patients with triple-class–exposed multiple myeloma. The drug significantly improved the